Literature DB >> 32770325

Paeonol suppresses the effect of ox-LDL on mice vascular endothelial cells by regulating miR-338-3p/TET2 axis in atherosclerosis.

Yunfu Yu1, Rui Yan1, Xiaozhen Chen1, Tao Sun1, Jifeng Yan2.   

Abstract

Atherosclerosis is the common vascular disease. Vascular smooth muscle cell proliferation and vascular endothelial cell (VEC) dysfunction are involved in the causes of atherosclerosis. And oxidized low-density lipoprotein (ox-LDL)-induced vascular endothelial cells (VECs) are suitable models for studying atherosclerosis development. Paeonol was reported to repress ox-LDL-induced VEC progression. However, its detailed mechanism was not fully reported. MicroRNAs (miRNAs) acted as regulators in multiple diseases. Previous findings found that microRNA-338-3p (miR-338-3p) was overexpressed in Atherosclerosis process. However, the function and underlying mechanism of miR-338-3p in ox-LDL-treated VECs needed to be elucidated. The purpose of this research was to reveal the role of miR-338-3p in paeonol-regulated ox-LDL-induced VEC progression. Cell counting kit-8 (CCK-8) and flow cytometry were employed to determine cell viability and apoptosis, respectively. Moreover, the levels of IL-6 and IL-1β were analyzed using enzyme-linked immunosorbent assay, as well as the contents of reactive oxygen species, lactate dehydrogenase, and malonic dialdehyde were investigated using related kits. Furthermore, quantitative real-time polymerase chain reaction was carried out to determine the expression of miR-338-3p. Western blot assay was conducted to detect the level of tet methylcytosine dioxygenase 2 (TET2). Besides, the interaction between miR-338-3p and TET2 was predicted by DIANA, and then confirmed by the dual-luciferase reporter assay and RNA immunoprecipitation assay. Ox-LDL repressed mice VEC viability, and promoted apoptosis, inflammatory response, and oxidative injury. Paeonol inhibited the effect of ox-LDL on the growth of the VECs. Furthermore, paeonol regulated VEC development via downregulating miR-338-3p expression. Interestingly, miR-338-3p targeted TET2 and inhibited TET2 expression. MiR-338-3p modulated ox-LDL-treated VEC growth through suppressing TET2 expression. We demonstrated that paeonol attenuated the effect of ox-LDL on the development of mice VECs via modulating miR-338-3p/TET2 axis, providing a theoretical basis for the treatment of AS.

Entities:  

Keywords:  Atherosclerosis; Ox-LDL; Paeonol; TET2; VECs; miR-338-3p

Mesh:

Substances:

Year:  2020        PMID: 32770325     DOI: 10.1007/s11010-020-03865-w

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  6 in total

1.  Circular RNA circ-ARFIP2 regulates proliferation, migration and invasion in human vascular smooth muscle cells via miR-338-3p-dependent modulation of KDR.

Authors:  Kun Qin; Ge Tian; Dong Zhou; Guangzhong Chen
Journal:  Metab Brain Dis       Date:  2021-04-10       Impact factor: 3.584

2.  A novel miR-338-3p/SLC1A5 axis reprograms retinal pigment epithelium to increases its resistance to high glucose-induced cell ferroptosis.

Authors:  Jing Zhou; Caoyu Sun; Xu Dong; Hui Wang
Journal:  J Mol Histol       Date:  2022-03-23       Impact factor: 2.611

3.  Paeonol suppresses lipid formation and promotes lipid degradation in adipocytes.

Authors:  Ji Li; Huan Gu
Journal:  Exp Ther Med       Date:  2021-11-25       Impact factor: 2.447

Review 4.  A review on therapeutical potential of paeonol in atherosclerosis.

Authors:  Wei Yu; Iqra Ilyas; Nasrin Aktar; Suowen Xu
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

5.  Paeonol inhibits the progression of intracerebral haemorrhage by mediating the HOTAIR/UPF1/ACSL4 axis.

Authors:  Zheng-Long Jin; Wen-Ying Gao; Shao-Jun Liao; Tao Yu; Qing Shi; Shang-Zhen Yu; Ye-Feng Cai
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

6.  Micro-RNA-338-3p Promotes the Development of Atherosclerosis by Targeting Desmin and Promoting Proliferation.

Authors:  Shiran Yan; Jing Chen; Teng Zhang; Jian Zhou; Ge Wang; Yanfen Li
Journal:  Mol Biotechnol       Date:  2021-06-07       Impact factor: 2.695

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.